CTS-21166

• Description :

  CTS-21166 is a blood-brain barrier-permeable and orally active BACE1 inhibitor. CTS-21166 reduces brain Aβ levels. CTS-21166 can be used in the research of Alzheimer's disease[1][2].

• UNSPSC :

  12352005

• Target :

  Amyloid-β; Beta-secretase

• Related Pathways :

  Neuronal Signaling

• Field of Research :

  Neurological Disease

• Smiles :

  O=C(C1=CC(N(C)S(=O)(C)=O)=CC(C(N[C@@H](C)[C@@H](C)C[C@@H](C)C(N[C@H](C(NC(C)C)=O)C(C)C)=O)=O)=C1)N[C@@H](C2=CC=CC=C2)C

• Molecular Formula :

  C34H51N5O6S

• Molecular Weight :

  657.86

• References & Citations :

  [1]Yan R. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13. |[2]Menting KW, et al. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease. Front Aging Neurosci. 2014 Jul 21;6:165.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  BACE1

• CAS Number :

  [1226777-95-2]